Press release

Pierre Fabre and Roche extend collaboration in oncology

16 May 2018

Pierre Fabre and Roche extend collaboration agreement on companion diagnostic development

May 16th 2018 – Castres, France – Pierre Fabre announced today the extension of a collaboration agreement with Roche on companion diagnostic development for W0101, Pierre Fabre’s new antibody drug conjugate (ADC) product candidate targeting Insulin-like Growth Factor 1 (IGF-1) receptor currently in the international Phase I/II clinical study in patients with relapsed or refractory solid tumours. This firstin-human trial, launched in 2017, is led by Principal Investigator Dr. Christophe Massard, Head of the Therapeutic Innovation and Early Clinical Trial Department at Gustave Roussy, Villejuif, France and involves other sites in France and Spain.

The initial collaboration was established for the development of a robust prototype immunohistochemistry (IHC) assay as a future companion diagnostic test for W0101. The collaboration was extended to the retrospective determination of IGF-1R expression in patients enrolled in the Phase I/II clinical study.

“This collaboration with Roche, the world leader in in vitro diagnostics and tissue-based cancer diagnostics, is an important step in advancing this novel therapeutic option for cancer patients whose tumours overexpress IGF-1R,” stated Dr. Alexandre Passioukov, VP Translational Medicine at Pierre Fabre Research Institute. “It is noteworthy that the IGR-1R antibody used in the diagnostic assay binds a different epitope than the antibody from the therapeutic construct, both developed by Pierre Fabre Research Institute.”»

About W0101:

W0101 is a first-in-class ADC targeting Insulin-like Growth Factor 1 (IGF-1) receptor discovered and developed at Institute de Recherche Pierre Fabre. IGF-1R has been recognised for its role in tumorigenesis and growth in a broad range of cancers W0101 is a novel approach leveraging the advantages of ADCs relying on a highly specific monoclonal antibody to selectively deliver a potent cytotoxic drug to tumour cells via IGF-1R-mediated internalisation. W0101 is designed for the treatment of patients with tumours overexpressing IGF-1R and is currently tested in a phase I clinical trial. Additional information on the clinical trial can be found at:

Press Contact:
Valérie Roucoules - +33 1 49 10 83 84 

Contact our press office